Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial

Table 1 Body weight over the course of the study, by group

Group	N	Mean	SD	Range	Median	IQR
FMT (n = 15)
Baseline	14	94.18	7.95	82.00–110.00	93.50	87.75–100.38
6 wk	14	93.86	9.94	82.00–114.00	93.00	85.00–100.50
6 mo	14	94.21	11.24	78.00–115.00	94.00	84.50–99.25
1 yr	14	95.79	11.05	81.00–116.00	95.00	86.50–102.25
Placebo (n = 13)
Baseline	12	91.28	10.60	82.00–120.00	89.50	83.25–94.50
6 wk	12	89.79	9.53	80.50–112.00	86.50	82.25–96.75
6 mo	12	89.58	10.87	77.00–115.00	88.50	81.25–93.75
1 yr	12	90.50	13.11	73.00–117.00	86.50	81.25–99.75

IQR: Interquartile range; FMT: Fecal microbiota transplantation.

Table 2 Glycated hemoglobin levels over the course of the study, by group

Group	N	Mean	SD	Range	Median	IQR
FMT (n = 15)
Baseline	11	6.75	1.09	5.60–8.90	6.30	6.10–7.60
6 wk	11	6.65	1.09	5.60–9.10	6.10	6.00–7.60
6 mo	11	6.95	1.19	5.40–9.50	6.50	6.20–7.70
1 yr	11	7.34	1.85	5.60–11.50	6.70	5.80–8.30
Placebo (n = 13)
Baseline	11	6.99	1.99	4.80–12.50	6.60	6.00–7.50
6 wk	11	6.75	1.38	5.00–10.20	6.30	6.00–7.40
6 mo	11	6.97	1.98	4.90–12.20	6.40	5.90–7.20
1 yr	11	7.29	2.56	4.90–13.80	6.30	5.90–8.10

IQR: Interquartile range; FMT: Fecal microbiota transplantation.